Only way to get IPD moving according to the expectations placed on it by a lot of analysts is to get sales going, simple as that. I know the clincial long term studies programmes being undertaken are critical to proving the economics of pre-emptive testing which is the crux of IPD's value proposition, but neverthelss the pace of sales is clearly dissapointing.
Quarter on quarter growth is anemic.
No mention of EU or ROW initiatives.
Today they announce that indigenous Americans have been added to the Federal employee health plan so now there are more covered lives? Seriously? Are they going to provide blow by blow growth updates of other health plans and package that up as reimbursement growth?
I think the Board needs to undertake a comprehensive review of sales strategy if we dont see that sales growth coming through this year. Particularly with the much hyped expansion of FDA approval to the legs.
You cant blame changes to the US health system forever. And this is clearly a risk of having a US only or US first strategy.
Agree that this is a critical year for IPD.
And Ive tried sending an email to investor relations at IPD and get error messages- that is clearly poor.
IPD Price at posting:
53.0¢ Sentiment: Hold Disclosure: Held
